Characteristics and Prognosis of "Acute Promyelocytic Leukemia-like" Nucleophosmin-1-Mutated Acute Myeloid Leukemia in a Retrospective Patient Cohort

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Oct 26

PMID 39457595

Authors

Vasiliki Papadopoulou

Giulia Schiavini

Gregoire Stalder

Valentin Basset

Jacqueline Schoumans

Mitja Nabergoj

Muriel Schaller

Affiliations

Soon will be listed here.

Abstract

AML with mutation is the largest subcategory of AML, representing about 35% of AML cases. It is characterized by CD34 negativity, which suggests a relatively differentiated state of the bulk of leukemic blasts. Notably, a significant subset of NPM1-mutated AML cases also exhibit HLA-DR negativity, classifying them as "double-negative", and mimicking, therefore, the CD34 HLA-DR immunophenotype of acute promyelocytic leukemia (APL). This study focuses on the "acute promyelocytic leukemia-like" ("APL-like") subset of NPM1-mutated AML, which can be challenging to distinguish from APL at presentation, prior to confirming RARa translocations. We aim to investigate the hematologic and immunophenotypic parameters that may aid to its distinction from APL. Additionally, we explore differences in genetic profile and prognosis between "APL-like" and "non-APL-like" NPM1-mutated AML cases. We conducted a retrospective evaluation of 77 NPM1-mutated AML cases and 28 APL cases. Morphological characteristics, hematologic parameters (such as DD/WBC and PT/WBC), and specific immunophenotypic markers (including SSC, CD64, and CD4) can assist in the early distinction of "APL-like" NPM1-mutated AML from APL. Regarding differences in genetic profiles and outcomes between "APL-like" and non-"APL-like" NPM1-mutated AML cases, we observed a significantly higher incidence of IDH1/2 /TET2 mutations, along with a significantly lower incidence of DNMT3A mutations in the "APL-like" subset compared to the non-"APL-like" subset. The frequency of Ras-pathway and FLT3 mutations did not differ between these last two groups, nor did their prognoses. Our findings contribute to a comprehensive characterization of NPM1-mutated AML, enhancing diagnostic accuracy and aiding in the detailed classification of the disease. This information may potentially guide targeted therapies or differentiation-based treatment strategies.

Citing Articles

Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications.

Guarnera L, Fabiani E, Falconi G, Silvestrini G, Catanoso M, Divona M Cancers (Basel). 2025; 16(24.

PMID: 39766091 PMC: 11674562. DOI: 10.3390/cancers16244192.

References

Ruminy P, Marchand V, Buchbinder N, Larson T, Joly B, Penther D . Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia. Leukemia. 2015; 30(3):757-60. DOI: 10.1038/leu.2015.177. View

Fang H, Wang S, Hu S, Konoplev S, Mo H, Liu W . Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. Cytometry B Clin Cytom. 2022; 102(4):283-291. DOI: 10.1002/cyto.b.22085. View

Fathi A, DiNardo C, Kline I, Kenvin L, Gupta I, Attar E . Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA Oncol. 2018; 4(8):1106-1110. PMC: 5885269. DOI: 10.1001/jamaoncol.2017.4695. View

Buradkar A, Bezerra E, Coltro G, Lasho T, Finke C, Gangat N . Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia. 2020; 35(2):644-649. DOI: 10.1038/s41375-020-0889-7. View

Potter N, Miraki-Moud F, Ermini L, Titley I, Vijayaraghavan G, Papaemmanuil E . Single cell analysis of clonal architecture in acute myeloid leukaemia. Leukemia. 2018; 33(5):1113-1123. PMC: 6451634. DOI: 10.1038/s41375-018-0319-2. View

Uckelmann H, Haarer E, Takeda R, Wong E, Hatton C, Marinaccio C . Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia. Cancer Discov. 2022; 13(3):746-765. PMC: 10084473. DOI: 10.1158/2159-8290.CD-22-0366. View

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N . Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016; 374(23):2209-2221. PMC: 4979995. DOI: 10.1056/NEJMoa1516192. View

Falini B, Brunetti L, Martelli M . How I diagnose and treat NPM1-mutated AML. Blood. 2020; 137(5):589-599. DOI: 10.1182/blood.2020008211. View

Gajendra S, Gupta R, Thakral D, Gupta S, Jain G, Bakhshi S . CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations. Int J Lab Hematol. 2022; 45(2):221-228. DOI: 10.1111/ijlh.14007. View

10.

Schlenk R, Dohner K, Kneba M, Gotze K, Hartmann F, Del Valle F . Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2008; 94(1):54-60. PMC: 2625424. DOI: 10.3324/haematol.13378. View

11.

Garrett-Bakelman F, Melnick A . Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics. 2016; 8(7):945-57. PMC: 5066133. DOI: 10.2217/epi-2016-0008. View

12.

Issa G, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M . The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023; 615(7954):920-924. PMC: 10060155. DOI: 10.1038/s41586-023-05812-3. View

13.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

14.

Charlton J, Jung E, Mattei A, Bailly N, Liao J, Martin E . TETs compete with DNMT3 activity in pluripotent cells at thousands of methylated somatic enhancers. Nat Genet. 2020; 52(8):819-827. PMC: 7415576. DOI: 10.1038/s41588-020-0639-9. View

15.

Schlenk R, Weber D, Krzykalla J, Kindler T, Wulf G, Hertenstein B . Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. Sci Rep. 2023; 13(1):14809. PMC: 10491626. DOI: 10.1038/s41598-023-41964-y. View

16.

Boutzen H, Saland E, Larrue C, De Toni F, Gales L, Castelli F . Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med. 2016; 213(4):483-97. PMC: 4821643. DOI: 10.1084/jem.20150736. View

17.

Ploumakis A, Coleman M . OH, the Places You'll Go! Hydroxylation, Gene Expression, and Cancer. Mol Cell. 2015; 58(5):729-41. DOI: 10.1016/j.molcel.2015.05.026. View

18.

Arana Rosainz M, Nguyen N, Wahed A, Lelenwa L, Aakash N, Schaefer K . Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation. Int J Lab Hematol. 2020; 43(2):218-226. DOI: 10.1111/ijlh.13357. View

19.

Papadopoulou V, Schoumans J, Basset V, Solly F, Pasquier J, Blum S . Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes. Hematology. 2023; 28(1):2180704. DOI: 10.1080/16078454.2023.2180704. View

20.

Martelli M, Rossi R, Venanzi A, Meggendorfer M, Perriello V, Martino G . Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. Blood. 2021; 138(25):2696-2701. PMC: 9037756. DOI: 10.1182/blood.2021012732. View